6 hours ago
FDB Expert to Highlight AI's Emerging Impacton ePrescribing Workflows During NCPDP Annual Conference
Educational Track Session will describe how innovations can improve accuracy, reduce manual steps, and enhance interoperability across prescribing and pharmacy settings
SOUTH SAN FRANCISCO, Calif., April 29, 2026 -- FDB (First Databank, Inc.), the leading provider of drug knowledge that helps healthcare professionals make precise medication decisions, announced that Brad Engels, senior product manager at FDB, will share insights on how AI is reshaping prescription processing across the care continuum at the National Council for Prescription Drug Programs (NCPDP) 2026 Annual Technology & Business Conference.
The educational track session, titled "First Steps of AI's Revolutionary Impact on Prescription Processing," will take place on Tuesday, May 5, from 9:15 a.m. to 10:15 a.m. at the NCPDP Annual Conference 2026 in Scottsdale, Ariz.
The conference, themed "The Heart of Health Information Exchange: Powering Interoperable Futures," takes place May 4-6 at the Westin Kierland Resort & Spa in Scottsdale.
"Prescription processing has long been burdened by manual steps that consume clinician and pharmacist time, introduce variability, and create friction across the care continuum," said Engels. "AI offers a meaningful opportunity to address these challenges by bringing structure, accuracy, and efficiency to the way prescriptions are created, transmitted, and fulfilled. We are excited to explore these possibilities with the NCPDP community."
The session will examine how structured content facilitated by AI can drive greater interoperability, automation, and better outcomes for prescribers, pharmacies, and patients when integrated with NCPDP SCRIPT transactions such as NewRx, RxChange, CancelRx, and RxFill.
Engels will explore how AI is enhancing accuracy, speed, and patient care at multiple stages of the prescribing and dispensing process. On the prescriber side, ambient AI technologies are emerging that can capture medications, allergies, and prescriber intent during patient encounters to pre-populate prescriptions, interpret SIG instructions, normalize dosing, and improve consistency. The result is cleaner NewRx messages, reducing the need for pharmacy callbacks and rework.
On the pharmacy side, AI-driven natural language processing capabilities are beginning to support SIG translation, dose normalization, days-supply calculation, and drug-utilization review cues. These capabilities can help streamline pharmacy processing, reduce RxChange cycles, and mitigate exposure to pharmacy benefit manager audits.
Additional insights will be shared during the session by Rachel DiVincenzo, PharmD, senior manager of health and wellness systems operations at Kroger Health.
FDB has been at the forefront of the ePrescribing evolution, building on decades of drug knowledge expertise to develop AI-native capabilities that support medication workflow automation. The company launched the first new ePrescribing network in two decades when it rolled out FDB Vela™ several years ago. Recently FDB introduced MedProof MCP™ Model Context Protocol (MCP) server technology for ePrescribing, along with intelligent workflow tools designed to help clinicians and pharmacists reduce administrative burden while maintaining clinical accuracy.
FDB MedProof MCP is an AI-native MCP integration framework that enables technology teams to confidently connect agentic systems and applications to standardized medication intelligence delivered in a patient-specific clinical context. FDB also offers FDB Script Agent™, a prescription automation agent that leverages ambient listening data to auto-queue structured prescription orders for clinician review, and FDB VerifyAssist™, a pharmacy workflow assistant that automatically surfaces the most relevant drug and patient data during medication order verification. This helps hospital pharmacists quickly identify orders that warrant closer review.
These capabilities reflect the broader trajectory that will be explored at NCPDP: how AI-driven structure and automation across the prescription lifecycle can reduce friction, improve accuracy, and deliver better outcomes for prescribers, pharmacies, and patients.
Learn more about FDB Vela, FDB MedProof MCP, FDB Script Agent and FDB VerifyAssist.
About FDB
FDB (First Databank) delivers clinically robust, workflow-integrated drug knowledge that is intuitive, patient-specific, and actionable, enabling more precise medication decisions at the point of care. Trusted for rigorous quality control, deep clinical expertise, and a collaborative approach, FDB helps improve patient safety, streamline operations, and enhance health outcomes. FDB's comprehensive drug databases and next-generation medication decision support solutions power healthcare information systems used by the majority of hospitals, physician practices, pharmacies, payers, and beyond, impacting millions of clinicians, business associates, and patients every day. For more information, visit www.fdbhealth.com, or follow us on LinkedIn and YouTube.
About Hearst Health
The mission of Hearst Health is to guide healthcare organizations by delivering essential intelligence and software that improve the quality, safety, and efficiency of care. Hearst Health has been innovating with care for more than 40 years, with a commitment to making a lasting positive impact on health. The Hearst Health companies — FDB, Homecare Homebase, MCG, MHK, QGenda, and Zynx Health — elevate care by informing and empowering participants across the health journey. Learn more at www.hearst.com/hearst-health and follow @Hearst Health on LinkedIn.
Media Contact
Supreme Communications for FDB
FDBPR@supremecomms.ai